Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only a small subset of the provided claims is supported by the supplied label excerpts (indication and drowsiness/impairment and listed adverse reactions). Most claims about motion sickness use, dosing/timing, and mechanistic statements are not supported by the supplied prescribing information excerpts and therefore are treated as unsupported.
Category Scores
Accurate Statements
Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults.
Supported by label section 1 (INDICATIONS AND USAGE): “Meclizine hydrochloride is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults.”
Meclizine can cause drowsiness.
Supported by label section 5.1: “Since drowsiness may occur… patients should be warned…”
Patients are advised to avoid driving or operating machinery until they know how meclizine affects them.
Supported by label section 5.1 and 17: 5.1 cautions against driving/operating dangerous machinery due to drowsiness; 17 states meclizine may impair potentially dangerous activities (operating machinery/vehicles).
Meclizine may impair patients' ability to engage in potentially dangerous activities such as operating machinery or vehicles.
Supported by label section 17 (PATIENT COUNSELING INFORMATION): “may impair their ability… such as operating machinery or vehicles.”
Meclizine can cause slowed reaction time.
Partially supported by label impairment language in 17 and driving/operating caution in 5.1, but the specific phrasing “slowed reaction time” is not explicitly stated in the provided excerpts.
Meclizine can cause drowsiness, dry mouth, headache, fatigue, vomiting, and on rare occasions blurred vision.
Supported by label section 17 and section 6 (ADVERSE REACTIONS) excerpt: “Anaphylactic reaction, drowsiness, dry mouth, headache, fatigue, and vomiting. On rare occasions blurred vision has been reported.”
Unsupported Statements
Meclizine is used to prevent symptoms caused by motion sickness.
Not supported by the supplied label excerpts; only vertigo/vestibular indications are present in the provided indication text.
Meclizine is used to treat symptoms caused by motion sickness.
Not supported by the supplied label excerpts.
Meclizine helps prevent nausea during travel related to motion sickness.
Not supported by the supplied label excerpts.
Meclizine helps prevent vomiting during travel related to motion sickness.
Not supported by the supplied label excerpts.
Meclizine helps prevent dizziness during travel related to motion sickness.
Not supported by the supplied label excerpts.
Meclizine is used for vertigo and other dizziness related to inner-ear problems.
Not supported by the supplied label excerpts beyond the specific wording about vertigo associated with vestibular-system diseases.
Meclizine is used for symptoms from labyrinth disorders.
Not supported by the supplied label excerpts.
Meclizine helps calm brain and inner-ear pathways involved in balance and nausea.
Mechanistic language not supported by the supplied label excerpts.
Meclizine reduces signals that trigger dizziness and vomiting.
Mechanistic language not supported by the supplied label excerpts.
Meclizine helps control vertigo- and motion-related symptoms by reducing signals that trigger dizziness and vomiting.
Includes motion-related indication and mechanism; neither is supported by supplied excerpts.
Meclizine helps with dizziness/"spinning" sensations when used as intended.
The supplied label excerpt supports vertigo associated with vestibular diseases in adults, but the broader “when used as intended” plus “spinning sensations” and implied coverage beyond the excerpt is not directly supported by the provided text.
Meclizine helps with nausea when used as intended.
No indication for nausea is supported by the supplied label excerpts (nausea appears only indirectly as “vomiting” adverse reaction; no nausea indication is provided).
Meclizine helps with vomiting, especially related to motion sickness, when used as intended.
Label excerpts provide vomiting as an adverse reaction, not as a motion-sickness treatment indication.
Meclizine is typically taken as needed for symptom control.
No dosage or “as needed” regimen is provided in the supplied label excerpts.
For motion sickness, meclizine is often taken before travel.
Not supported by the supplied label excerpts and includes an unprovided indication/dosing regimen.
For dizziness/vertigo, meclizine is taken to manage ongoing symptoms.
No dosage/frequency/duration statements are provided in the supplied excerpts.
Exact timing and dosing of meclizine depend on the specific product and the patient's age/condition.
No dosing instructions are provided in the supplied label excerpts.
Meclizine is an antihistamine medication.
Not supported by the supplied label excerpts (no pharmacologic class statement provided).
Meclizine works as an antihistamine.
Not supported by the supplied label excerpts.
Meclizine can interact with other medications that cause sedation.
While the excerpts reference drug interactions generally (“[see Drug Interactions (7.1, 7.2)]”), the supplied text does not include specific sedation-interaction claims.
Meclizine can cause slowed reaction time.
The supplied excerpts caution about driving/operating machinery and impairment of potentially dangerous activities, but do not explicitly state “slowed reaction time.”
Meclizine helps prevent nausea during travel related to motion sickness.
Not supported by the supplied label excerpts.
Contradictions
Low
AI Statement
Meclizine is used to treat symptoms caused by motion sickness.
Label Reference
Label section 1 (INDICATIONS AND USAGE) in provided excerpt supports vertigo associated with vestibular-system diseases in adults; no motion sickness indication is provided in supplied text.
Important Omissions
Motion sickness prevention/treatment dosing, timing, and indication wording as required to substantiate multiple related claims.
Importance:
High
Explicit label statements regarding antihistamine mechanism/class and “inner-ear pathways”/signal-reduction mechanism.
Importance:
Moderate
Specific drug interaction details (e.g., other sedating medications) referenced but not included in the supplied excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims extend beyond provided on-label indication/excerpts (notably motion-sickness use and dosing/timing) and include mechanistic/pharmacologic and interaction statements that are not supported by the supplied label text. The label-supported drowsiness/impairment and adverse reaction counseling reduces risk for the subset of accurate safety messaging.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most motion-sickness-related indications, dosing/timing, antihistamine/mechanism, and sedation-interaction claims are not supported by the supplied FDA label excerpts; only vertigo indication and certain drowsiness/adverse reaction statements are supported.
Suggested Improvement
Limit claims to the provided label-supported indication (adult vertigo associated with vestibular-system diseases) and label-supported safety counseling (drowsiness/avoid driving or dangerous machinery; impairment of potentially dangerous activities) and adverse reactions listed (including blurred vision on rare occasions). Remove or explicitly qualify unsupported motion-sickness, antihistamine/class/mechanism, and drug interaction specifics unless the full prescribing information sections substantiate them.